Terns Pharmaceuticals, Inc. (TERN) Stock Price, Financials & Summary

Price chart

Apr 9Apr 14Apr 17Apr 22Apr 27Apr 30May 5May 15

Key dataMay 15, 2026

Open$52.97

From 52W high−0.41%

Volume6.33M

Market cap$6.12B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataMay 15, 2026

Open

$52.97

From 52W high

−0.41%

Volume

6.33M

Market cap

$6.12B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−46.3x

P/E (TTM)

—

RSI (14)

73.9

MomentumView details →

1D Return

−0.03%

YTD Return

+31.06%

SummaryUpdated Dec 1, 2025

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Foster City, California. The company went public in February 2021 and focuses on developing innovative small-molecule therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and obesity. As a clinical-stage company, Terns has no approved products on the market and is currently advancing multiple drug candidates through various phases of clinical trials.

Ask drillr about Terns Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−46.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

6.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−9.56%

ROA (TTM)

−9.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+8.85%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+8.04%

EBITDA YoY

−9.06%

MomentumView details →

1D Return

−0.03%

YTD Return

+31.06%

1Y Return

+1738.54%

RSI (14)

73.9

vs 50D SMA

+5.57%

vs 200D SMA

+84.53%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

62.41x

Quick Ratio

62.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

13.33%

Beats (12Q)

8/12

Next Q EPS Est

—

Avg Surprise (4Q)

10.92%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−96.21M

Op. CF (TTM)

−82.18M

Latest newsMore news →

Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.35d ago

Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.47d ago

Similar companies

Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H02335.HK 科前生物688526.SH Kiniksa Pharmaceuticals, Ltd.KNSA Liquidia CorporationLQDA Centessa Pharmaceuticals plcCNTA Mirum Pharmaceuticals, Inc.MIRM Find similar companies →

Latest newsMore news →

Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.35d ago Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.47d ago Merck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.51d ago